Pharmaceuticals Company Investment Opportunity in Delhi, India
|Employees||100 - 500|
|Legal Entity||Public Limited Company|
|Reported Sales||USD 21 million|
|Run Rate Sales||USD 21 million|
|EBITDA Margin||13 %|
|Locations||Delhi + 1 more|
|Local Time||9:38 PM Asia / Kolkata|
|Listed By||Advisor / Business Broker|
- Annual capacity of 300MT to manufacture Sterile API.
- Having world class R&D setup recognized by DST, GOI.
- Well-established clientele in India and also export its product to Asia pacific regions, North Africa, South America etc.
- Having various FDA approval such as Schedule M, FDA Govt. of India, WHO GMP, ANVISA GMP.
- Having 2 dedicated manufacturing units.
Bulk Sterile API.
Proton Pump Inhibitors.
General Formulation such as - Acyclovir for injection 500mg / vial, Ketoprofen for injection 100mg / vial etc.
- Having a 2 manufacturing units covered in area of 9800 sq meters.
- Manufacturing facility confined to ground floor, first floor.
- Unit 1 is WHO GMP approved.
- Unit II- EU / ANVISA approved.
- Corporate office is in Delhi.
Earlier than 15 daysManaging Director, Delhi, Financial Consultant connected with the Business
Earlier than 15 daysDirector, Noida, M&A Advisor connected with the Business
Earlier than 15 daysBusiness Consultant, Technology & Capital Solutions, Hyderabad, Corporate Investor / Buyer connected with the Business